As mentioned above, PD-1 inhibitors changed treatment algorithms in recurrent and/or metastatic HNSCC as pembrolizumab was approved for first line treatment either alone or in combination with chemotherapy. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.